CompletedNCT03834753
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 228 planned enrolment
- Countries listed
- 1
- Registry update
- August 3, 2026
Registry Intervention View
bevacizumab
Trial registrations containing the exact intervention label bevacizumab.
Exact registry label · Not reported
32 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
9 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT06190093
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 400 planned enrolment
- Countries listed
- 1
- Registry update
- July 23, 2026
CompletedNCT04516278
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
PHASE3 · 197 planned enrolment
- Countries listed
- 1
- Registry update
- July 17, 2026
Active Not RecruitingNCT05112861
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
PHASE3 · 120 planned enrolment
- Countries listed
- 1
- Registry update
- April 22, 2026
Active Not RecruitingNCT03451370
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Phase not reported · 121 planned enrolment
- Countries listed
- 1
- Registry update
- April 15, 2026
RecruitingNCT06952452
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
PHASE3 · 630 planned enrolment
- Countries listed
- 1
- Registry update
- November 20, 2025
CompletedNCT03844074
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 61 planned enrolment
- Countries listed
- 1
- Registry update
- March 19, 2025
TerminatedNCT02387957
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
PHASE2 · 63 planned enrolment
- Countries listed
- 1
- Registry update
- October 30, 2024
UnknownNCT05273814
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
PHASE1 · 30 planned enrolment
- Countries listed
- 1
- Registry update
- July 13, 2022
CompletedNCT05110209
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Phase not reported · 331,541 planned enrolment
- Countries listed
- 1
- Registry update
- December 21, 2021
CompletedNCT05146687
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Phase not reported · 369,600 planned enrolment
- Countries listed
- 1
- Registry update
- December 16, 2021
CompletedNCT01027468
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Phase not reported · 160 planned enrolment
- Countries listed
- 0
- Registry update
- April 24, 2019
CompletedNCT03552770
Single or Combined Protocols for NV-AMD
PHASE4 · 109 planned enrolment
- Countries listed
- 0
- Registry update
- June 12, 2018
CompletedNCT00593450
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
PHASE3 · 1,208 planned enrolment
- Countries listed
- 1
- Registry update
- August 21, 2017
TerminatedNCT00351039
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
PHASE1 · PHASE2 · 8 planned enrolment
- Countries listed
- 1
- Registry update
- March 23, 2017
CompletedNCT02118831
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
PHASE1 · PHASE2 · 56 planned enrolment
- Countries listed
- 0
- Registry update
- May 19, 2016
WithdrawnNCT02036723
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
PHASE3 · 0 planned enrolment
- Countries listed
- 2
- Registry update
- March 31, 2016
CompletedNCT01032109
Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
Phase not reported · 45 planned enrolment
- Countries listed
- 1
- Registry update
- February 26, 2016
CompletedNCT00727753
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
Phase not reported · 54 planned enrolment
- Countries listed
- 1
- Registry update
- May 28, 2015
CompletedNCT01127360
LUCAS (Lucentis Compared to Avastin Study)
PHASE4 · 420 planned enrolment
- Countries listed
- 1
- Registry update
- January 16, 2015
CompletedNCT00484939
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
PHASE3 · 280 planned enrolment
- Countries listed
- 12
- Registry update
- January 8, 2015
CompletedNCT00805649
Combined Therapy in Age-Related Macular Degeneration (ARMD)
PHASE4 · 150 planned enrolment
- Countries listed
- 1
- Registry update
- September 27, 2012
CompletedNCT00556348
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
PHASE4 · 500 planned enrolment
- Countries listed
- 0
- Registry update
- November 22, 2011
CompletedNCT00376701
Combination Therapy for Age-Related Macular Degeneration.
PHASE2 · 103 planned enrolment
- Countries listed
- 1
- Registry update
- September 28, 2011
CompletedNCT01327222
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 20 planned enrolment
- Countries listed
- 1
- Registry update
- April 1, 2011
CompletedNCT01306591
Bevacizumab for Neovascular Age-related Macular Degeneration
Phase not reported · 210 planned enrolment
- Countries listed
- 1
- Registry update
- March 2, 2011
CompletedNCT01024504
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
PHASE2 · 46 planned enrolment
- Countries listed
- 1
- Registry update
- April 9, 2010
CompletedNCT00531024
Systemic Avastin Therapy in Age-Related Macular Degeneration
PHASE2 · PHASE3 · 30 planned enrolment
- Countries listed
- 1
- Registry update
- April 22, 2009
UnknownNCT00559715
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
PHASE3 · 366 planned enrolment
- Countries listed
- 1
- Registry update
- March 26, 2009
CompletedNCT00407719
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
PHASE1 · 10 planned enrolment
- Countries listed
- 0
- Registry update
- February 3, 2009
CompletedNCT00370786
Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
PHASE3 · 31 planned enrolment
- Countries listed
- 1
- Registry update
- July 11, 2008
UnknownNCT00370370
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
PHASE3 · planned enrolment not reported
- Countries listed
- 1
- Registry update
- June 26, 2008